Placebo + Pregabalin + Pregabalin + Pregabalin

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Neuralgia, Postherpetic

Conditions

Neuralgia, Postherpetic

Trial Timeline

Sep 1, 2006 → Nov 1, 2007

NCT ID

NCT00394901

About Placebo + Pregabalin + Pregabalin + Pregabalin

Placebo + Pregabalin + Pregabalin + Pregabalin is a phase 3 stage product being developed by Pfizer for Neuralgia, Postherpetic. The current trial status is completed. This product is registered under clinical trial identifier NCT00394901. Target conditions include Neuralgia, Postherpetic.

What happened to similar drugs?

8 of 17 similar drugs in Neuralgia, Postherpetic were approved

Approved (8) Terminated (3) Active (7)

✅QUTENZAAstellas PharmaApproved

✅GalcanezumabEli LillyApproved

🔄Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/dayJiangsu Hengrui MedicinePhase 3

✅Etoricoxib + PlaceboMerckApproved

✅pregabalinPfizerApproved

✅Lyrica (pregabalin) + PlaceboPfizerApproved

🔄placebo + pregabalinPfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00394901	Phase 3	Completed	Sep 1, 2006	Nov 1, 2007	Neuralgia, Postherpetic

Competing Products

20 competing products in Neuralgia, Postherpetic

See all competitors

Product	Company	Stage	Hype Score
Placebo + DS-5565	Daiichi Sankyo	Pre-clinical	26
QUTENZA	Astellas Pharma	Approved	43
ASP8477 + Placebo	Astellas Pharma	Phase 2	35
E2007 (perampanel) + Placebo	Eisai	Phase 2	35
E2007	Eisai	Phase 2/3	38
KHK6188 + Placebo	Kyowa Kirin	Phase 2	35
ONO-1110 + Placebo	Ono Pharmaceutical	Phase 2	39
Galcanezumab	Eli Lilly	Approved	43
Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day	Jiangsu Hengrui Medicine	Phase 3	36
ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine	AbbVie	Phase 2	35
MK-8291 + Placebo	Merck	Phase 1	29
Etoricoxib + Placebo	Merck	Approved	39
Cetuximab + Placebo	Merck	Phase 2	35
ADL5747 + Placebo + Pregabalin	Merck	Phase 2	27
MK0759	Merck	Phase 2	27
MK0686	Merck	Phase 2	27
Comparator: pregabalin + Comparator: Placebo (unspecified)	Merck	Phase 1	29
EMA401 + Placebo	Novartis	Phase 2	27
pregabalin	Pfizer	Approved	43
Lyrica (pregabalin) + Placebo	Pfizer	Approved	43